{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:08:52Z","timestamp":1790100532792,"version":"4.0.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s40261-016-0457-0","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T18:11:47Z","timestamp":1472839907000},"page":"7-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature"],"prefix":"10.1007","volume":"37","author":[{"given":"Sherif Hanafy","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"457_CR1","unstructured":"Aronoff GR, American College of Physicians. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2007."},{"key":"457_CR2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1034\/j.1399-6576.2001.450802.x","volume":"45","author":"JF Bugge","year":"2001","unstructured":"Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand. 2001;45:929\u201334.","journal-title":"Acta Anaesthesiol Scand"},{"key":"457_CR3","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ki.2011.322","volume":"80","author":"GR Matzke","year":"2011","unstructured":"Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:1122\u201337.","journal-title":"Kidney Int"},{"key":"457_CR4","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1046\/j.1523-1755.56.s.72.2.x","volume":"56","author":"J Bohler","year":"1999","unstructured":"Bohler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int. 1999;56:S24\u20138.","journal-title":"Kidney Int."},{"key":"457_CR5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2215\/CJN.05630614","volume":"10","author":"TD Nolin","year":"2015","unstructured":"Nolin TD, Aronoff GR, Fissell WH, et al. Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative. Clin J Am Soc Nephrol. 2015;10:159\u201364.","journal-title":"Clin J Am Soc Nephrol"},{"key":"457_CR6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1060028015591845","volume":"49","author":"JM Louie","year":"2015","unstructured":"Louie JM, Raphael KL, Barker B. Levetiracetam use with continuous renal replacement therapy. Ann Pharmacother. 2015;49:1079\u201380.","journal-title":"Ann Pharmacother"},{"key":"457_CR7","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1002\/phar.1615","volume":"35","author":"SD Nei","year":"2015","unstructured":"Nei SD, Wittwer ED, Kashani KB, Frazee EN. Levetiracetam pharmacokinetics in a patient receiving continuous venovenous hemofiltration and venoarterial extracorporeal membrane oxygenation. Pharmacotherapy. 2015;35:e127\u201330.","journal-title":"Pharmacotherapy"},{"key":"457_CR8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12028-016-0242-1","volume":"25","author":"AM New","year":"2016","unstructured":"New AM, Nei SD, Kashani KB, Rabinstein AA, Frazee EN. Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction. Neurocrit Care. 2016;25:141\u20134.","journal-title":"Neurocrit Care."},{"key":"457_CR9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ki.1986.276","volume":"30","author":"TA Golper","year":"1986","unstructured":"Golper TA, Saad AM. Gentamicin and phenytoin sieving through hollow-fiber polysulfone hemofilters. Kidney Int. 1986;30:937\u201343.","journal-title":"Kidney Int"},{"key":"457_CR10","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1177\/1060028013503131","volume":"47","author":"KM Oltrogge","year":"2013","unstructured":"Oltrogge KM, Peppard WJ, Saleh M, Regner KR, Herrmann DJ. Phenytoin removal by continuous venovenous hemofiltration. Ann Pharmacother. 2013;47:1218\u201322.","journal-title":"Ann Pharmacother"},{"key":"457_CR11","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1345\/aph.1P308","volume":"45","author":"MMR Maat De","year":"2011","unstructured":"De Maat MMR, Van Leeuwen HJ, Edelbroek PM. High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy. Ann Pharmacother. 2011;45:e18.","journal-title":"Ann Pharmacother"},{"key":"457_CR12","first-page":"134","volume":"30","author":"JA Goncalves","year":"2010","unstructured":"Goncalves JA, Santos C, Montalban JM. et al [Continuous venovenous haemodiafiltration as a solution for acute intoxication with sodium valproate]. Nefrologia. 2010;30:134\u20135.","journal-title":"Nefrologia"},{"key":"457_CR13","doi-asserted-by":"crossref","unstructured":"Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22:255\u201371, vi.","DOI":"10.1016\/j.ccc.2006.02.011"},{"key":"457_CR14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/0971-4065.83744","volume":"22","author":"AK Guddati","year":"2012","unstructured":"Guddati AK, Zafar Z, Cheng JT, Mohan S. Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy. Indian J Nephrol. 2012;22:59\u201361.","journal-title":"Indian J Nephrol"},{"key":"457_CR15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/clpt.1994.118","volume":"56","author":"RA Blum","year":"1994","unstructured":"Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994;56:154\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"457_CR16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"PN Patsalos","year":"2004","unstructured":"Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707\u201324.","journal-title":"Clin Pharmacokinet"},{"key":"457_CR17","unstructured":"Bauer LA. Applied clinical pharmacokinetics. 2nd ed. New York: McGraw-Hill Medical; 2008. p. xiv, 826."},{"key":"457_CR18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/hdi.12132","volume":"18","author":"YK Chung","year":"2014","unstructured":"Chung YK, Chang KY, Park HS, et al. Severe carbamazepine intoxication unresponsive to albumin-enhanced continuous venovenous hemodiafiltration with low dialysate flow. Hemodial Int. 2014;18:551\u20135.","journal-title":"Hemodial Int"},{"key":"457_CR19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5414\/CN108290","volume":"83","author":"A Payette","year":"2015","unstructured":"Payette A, Ghannoum M, Madore F, Albert M, Troyanov S, Bouchard J. Carbamazepine poisoning treated by multiple extracorporeal treatments. Clin Nephrol. 2015;83:184\u20138.","journal-title":"Clin Nephrol"},{"key":"457_CR20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/15563650.2016.1148721","volume":"54","author":"CG Smollin","year":"2016","unstructured":"Smollin CG, Petrie MS, Kearney T. Carbamazepine and carbamazepine-10,11-epoxide clearance measurements during continuous venovenous hemofiltration in a massive overdose. Clin Toxicol (Phila). 2016;54:424\u20137.","journal-title":"Clin Toxicol (Phila)"},{"key":"457_CR21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00134-012-2717-7","volume":"39","author":"JS Choi","year":"2013","unstructured":"Choi JS, Kim CS, Bae EH, et al. Enhanced clearance of carbamazepine using albumin-containing dialysate during CVVHDF. Intensive Care Med. 2013;39:159\u201360.","journal-title":"Intensive Care Med"},{"key":"457_CR22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1542-4758.2011.00563.x","volume":"15","author":"JL Harder","year":"2011","unstructured":"Harder JL, Heung M, Vilay AM, Mueller BA, Segal JH. Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose. Hemodial Int. 2011;15:412\u20135.","journal-title":"Hemodial Int"},{"key":"457_CR23","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/15563650.2014.973572","volume":"52","author":"M Ghannoum","year":"2014","unstructured":"Ghannoum M, Yates C, Galvao TF, et al. Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2014;52:993\u20131004.","journal-title":"Clin Toxicol (Phila)"},{"key":"457_CR24","doi-asserted-by":"crossref","unstructured":"Ritschel WA, Kearns GL, American Pharmacists Association. Handbook of basic pharmacokinetics\u2014including clinical applications. 7th ed. Washington, D.C.: American Pharmacists Association; 2009.","DOI":"10.21019\/9781582121260"},{"key":"457_CR25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0272-6386(99)70076-4","volume":"34","author":"S Brunet","year":"1999","unstructured":"Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34:486\u201392.","journal-title":"Am J Kidney Dis"},{"key":"457_CR26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00063-015-0046-7","volume":"111","author":"M Ruhe","year":"2016","unstructured":"Ruhe M, Grautoff S, Kahler J, Pohle T. Suicide attempt by means of phenobarbital overdose: Effective treatment with continuous veno-venous hemodialysis [German]. Medizinische Klinik-Intensivmedizin und Notfallmedizin. 2016;111:141\u20134.","journal-title":"Medizinische Klinik-Intensivmedizin und Notfallmedizin"},{"key":"457_CR27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jns.2009.10.001","volume":"288","author":"L Browning","year":"2010","unstructured":"Browning L, Parker D Jr, Liu-DeRyke X, Shah A, Coplin WM, Rhoney DH. Possible removal of topiramate by continuous renal replacement therapy. J Neurol Sci. 2010;288:186\u20139.","journal-title":"J Neurol Sci"},{"key":"457_CR28","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1097\/MD.0000000000000046","volume":"93","author":"S Rosenborg","year":"2014","unstructured":"Rosenborg S, Saraste L, Wide K. High phenobarbital clearance during continuous renal replacement therapy: a case report and pharmacokinetic analysis. Medicine (Baltimore). 2014;93:e46.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"457_CR29","first-page":"757","volume":"52","author":"M Boyd","year":"2014","unstructured":"Boyd M, Proschek C, Kazzi Z. Massive lacosamide overdose treated with continuous renal replacement therapy. Clin Toxicol. 2014;52(7):757\u20138.","journal-title":"Clin Toxicol"},{"key":"457_CR30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/15563650.2015.1035441","volume":"53","author":"M Ghannoum","year":"2015","unstructured":"Ghannoum M, Laliberte M, Nolin TD, et al. Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2015;53:454\u201365.","journal-title":"Clin Toxicol (Phila)"},{"key":"457_CR31","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239\u201376.","journal-title":"Epilepsia"},{"key":"457_CR32","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s001340100965","volume":"27","author":"T Tsubo","year":"2001","unstructured":"Tsubo T, Sakai I, Okawa H, Ishihara H, Matsuki A. Ketamine and midazolam kinetics during continuous hemodiafiltration in patients with multiple organ dysfunction syndrome. Intensive Care Med. 2001;27:1087\u201390.","journal-title":"Intensive Care Med"},{"key":"457_CR33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.ajkd.2004.09.004","volume":"45","author":"EL Swart","year":"2005","unstructured":"Swart EL, de Jongh J, Zuideveld KP, Danhof M, Thijs LG, Strack van Schijndel RJ. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis. 2005;45:360\u201371.","journal-title":"Am J Kidney Dis"},{"key":"457_CR34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/00912700122010933","volume":"41","author":"M Bolon","year":"2001","unstructured":"Bolon M, Bastien O, Flamens C, Paulus S, Boulieu R. Midazolam disposition in patients undergoing continuous venovenous hemodialysis. J Clin Pharmacol. 2001;41:959\u201362.","journal-title":"J Clin Pharmacol"},{"key":"457_CR35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/08860229609052800","volume":"18","author":"E Bironneau","year":"1996","unstructured":"Bironneau E, Garrec F, Kergueris MF, Testa A, Nicolas F. Hemodiafiltration in pentobarbital poisoning. Ren Fail. 1996;18:299\u2013303.","journal-title":"Ren Fail"},{"key":"457_CR36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4103\/0972-5229.138159","volume":"18","author":"S Jana","year":"2014","unstructured":"Jana S, Chakravarty C, Taraphder A, Ramasubban S. Successful use of sustained low efficiency dialysis in a case of severe phenobarbital poisoning. Indian J Crit Care Med. 2014;18:530\u20132.","journal-title":"Indian J Crit Care Med"},{"key":"457_CR37","first-page":"230","volume":"14","author":"F Khan","year":"2014","unstructured":"Khan F, Menon U, Sagastume R, Eugene Ramsay R. Clearance of valproic acid by continuous renal replacement therapy in a patient with status epilepticus. Epilepsy Curr. 2014;14:230\u20131.","journal-title":"Epilepsy Curr"},{"key":"457_CR38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10047-014-0754-4","volume":"17","author":"R Narayan","year":"2014","unstructured":"Narayan R, Rizzo M, Cole M. Successful treatment of severe carbamazepine toxicity with 5\u00a0% albumin-enhanced continuous venovenous hemodialysis. J Artif Organs. 2014;17:206\u20139.","journal-title":"J Artif Organs"},{"key":"457_CR39","unstructured":"Vo M, Zhang J, Melhem S, Polderman KH, Shutter LA. Extracorporeal therapy for the management of phenytoin toxicity. Neurocrit Care. 2014;1:S135."},{"key":"457_CR40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/15563650.2012.746694","volume":"51","author":"S Ray","year":"2013","unstructured":"Ray S, Skellett S. Valproate toxicity in a child: two novel observations. Clin Toxicol. 2013;51:60.","journal-title":"Clin Toxicol"},{"key":"457_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bcr--006891.","volume":"2012","author":"S Shah","year":"2012","unstructured":"Shah S, Tomlin M, Sparkes D. Lack of effect of high-volume continuous veno-venous haemofiltration with dialysis in massive carbamazepine overdose. BMJ Case Rep. 2012;2012:bcr2012006891. doi: 10.1136\/bcr--006891.","journal-title":"BMJ Case Rep"},{"issue":"260","key":"457_CR42","first-page":"e1","volume":"28","author":"U Goktas","year":"2010","unstructured":"Goktas U, Kati I, Yuce HH. Management of a severe carbamazepine overdose with continuous venovenous hemodiafiltration. Am J Emerg Med. 2010;28(260):e1\u20132.","journal-title":"Am J Emerg Med"},{"issue":"3","key":"457_CR43","first-page":"248","volume":"48","author":"EA Luzhnikov","year":"2010","unstructured":"Luzhnikov EA, Sukhodolova GN, Ostapenko YN, Kovalenko LA, Kovalchuk AS, Dolginov DM. A case of successful therapy in acute valproic acid poisoning in a child using hemodiafiltration. Clin Toxicol. 2010;48(3):248.","journal-title":"Clin Toxicol"},{"key":"457_CR44","first-page":"60","volume":"1","author":"FM Jacobs","year":"2008","unstructured":"Jacobs FM, Pinot G, Prat D, Pilorge C, Brivet FG. Valproic acid overdose and continuous venovenous haemodiafiltration. NDT Plus. 2008;1:60\u20131.","journal-title":"NDT Plus"},{"key":"457_CR45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1542-4758.2008.00254.x","volume":"12","author":"E Khan","year":"2008","unstructured":"Khan E, Huggan P, Celi L, Macginley R, Schollum J, Walker R. Sustained low-efficiency dialysis with filtration (SLEDD-f) in the management of acute sodium valproate intoxication. Hemodial Int. 2008;12:211\u20134.","journal-title":"Hemodial Int"},{"key":"457_CR46","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1053\/j.ajkd.2006.04.081","volume":"48","author":"R Lal","year":"2006","unstructured":"Lal R, Faiz S, Garg RK, Baweja KS, Guntupalli J, Finkel KW. Use of continuous venovenous hemodiafiltration in a case of severe phenobarbital poisoning. Am J Kidney Dis. 2006;48:e13\u20135.","journal-title":"Am J Kidney Dis"},{"key":"457_CR47","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1460-9592.2006.01955.x","volume":"16","author":"TS Yildiz","year":"2006","unstructured":"Yildiz TS, Toprak DG, Arisoy ES, Solak M, Toker K. Continuous venovenous hemodiafiltration to treat controlled-release carbamazepine overdose in a pediatric patient. Paediatr Anaesth. 2006;16:1176\u20138.","journal-title":"Paediatr Anaesth"},{"key":"457_CR48","doi-asserted-by":"crossref","unstructured":"Al Aly Z, Yalamanchili P, Gonzalez E. Extracorporeal management of valproic acid toxicity: a case report and review of the literature. Semin Dial. 2005;18:62\u20136.","DOI":"10.1111\/j.1525-139X.2005.18106.x"},{"key":"457_CR49","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1542\/peds.113.2.406","volume":"113","author":"DJ Askenazi","year":"2004","unstructured":"Askenazi DJ, Goldstein SL, Chang IF, Elenberg E, Feig DI. Management of a severe carbamazepine overdose using albumin-enhanced continuous venovenous hemodialysis. Pediatrics. 2004;113:406\u20139.","journal-title":"Pediatrics"},{"key":"457_CR50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5414\/CNP59056","volume":"59","author":"TD Kay","year":"2003","unstructured":"Kay TD, Playford HR, Johnson DW. Hemodialysis versus continuous veno-venous hemodiafiltration in the management of severe valproate overdose. Clin Nephrol. 2003;59:56\u20138.","journal-title":"Clin Nephrol"},{"key":"457_CR51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","volume":"56","author":"PN Patsalos","year":"2015","unstructured":"Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56:12\u201327.","journal-title":"Epilepsia"},{"key":"457_CR52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/15748847113089990053","volume":"8","author":"DJ Tompson","year":"2013","unstructured":"Tompson DJ, Crean CS. Clinical pharmacokinetics of retigabine\/ezogabine. Curr Clin Pharmacol. 2013;8:319\u201331.","journal-title":"Curr Clin Pharmacol"},{"key":"457_CR53","doi-asserted-by":"crossref","unstructured":"Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004;13 Suppl 1:S5\u20139, (discussion S10).","DOI":"10.1016\/j.seizure.2004.04.016"},{"key":"457_CR54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1528-1157.1995.tb02575.x","volume":"36","author":"LE Gustavson","year":"1995","unstructured":"Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia. 1995;36:605\u201311.","journal-title":"Epilepsia"},{"key":"457_CR55","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","volume":"49","author":"E Perucca","year":"2008","unstructured":"Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123\u201341.","journal-title":"Epilepsia"},{"key":"457_CR56","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1552-4604.1983.tb01799.x","volume":"23","author":"RH Levy","year":"1983","unstructured":"Levy RH, Lin HS, Blehaut HM, Tor JA. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol. 1983;23:523\u201333.","journal-title":"J Clin Pharmacol"},{"key":"457_CR57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","volume":"66","author":"P Rolan","year":"2008","unstructured":"Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66:71\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"457_CR58","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","volume":"42","author":"TW May","year":"2003","unstructured":"May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42:1023\u201342.","journal-title":"Clin Pharmacokinet"},{"key":"457_CR59","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S5189","volume":"5","author":"C Kellinghaus","year":"2009","unstructured":"Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag. 2009;5:757\u201366.","journal-title":"Ther Clin Risk Manag"},{"key":"457_CR60","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1528-1167.2010.02751.x","volume":"52","author":"C Greenaway","year":"2011","unstructured":"Greenaway C, Ratnaraj N, Sander JW, Patsalos PN. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia. 2011;52:258\u201363.","journal-title":"Epilepsia"},{"key":"457_CR61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/B978-0-7020-4086-3.00027-8","volume":"119","author":"JJ Asconape","year":"2014","unstructured":"Asconape JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol. 2014;119:417\u201332.","journal-title":"Handb Clin Neurol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0457-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0457-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0457-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0457-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T01:32:16Z","timestamp":1718760736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0457-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0457-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}